Literature DB >> 16174888

Phenytoin poisoning.

Simon Craig1.   

Abstract

Phenytoin toxicity may result from intentional overdose, dosage adjustments, drug interactions, or alterations in physiology. Intoxication manifests predominantly as nausea, central nervous system dysfunction (particularly confusion, nystagmus, and ataxia), with depressed conscious state, coma, and seizures occurring in more severe cases. Cardiac complications such as arrhythmias and hypotension are rare in cases of phenytoin ingestion, but they may be seen in parenteral administration of phenytoin or fosphenytoin. Deaths are unlikely after phenytoin intoxication alone. A greatly increased half-life in overdose due to zero-order pharmacokinetics can result in a prolonged duration of symptoms and thus prolonged hospitalization with its attendant complications. The mainstay of therapy for a patient with phenytoin intoxication is supportive care. Treatment includes attention to vital functions, management of nausea and vomiting, and prevention of injuries due to confusion and ataxia. There is no antidote, and there is no evidence that any method of gastrointestinal decontamination or enhanced elimination improves outcome. Activated charcoal should be considered if the patient presents early; however, the role of multiple-dose activated charcoal is controversial. Experimental studies have proven increased clearance rates, but this effect has not been translated into clinical benefit. There is no evidence that any invasive method of enhanced elimination (such as plasmapheresis, hemodialysis, or hemoperfusion) provides any benefit. This article provides an overview of phenytoin pharmacokinetics and the clinical manifestations of toxicity, followed by a detailed review of the various treatment modalities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16174888     DOI: 10.1385/NCC:3:2:161

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  82 in total

1.  Charcoal hemoperfusion in the treatment of phenytoin overdose.

Authors:  C Kawasaki; R Nishi; S Uekihara; S Hayano; M Otagiri
Journal:  Am J Kidney Dis       Date:  2000-02       Impact factor: 8.860

2.  2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.

Authors:  William A Watson; Toby L Litovitz; George C Rodgers; Wendy Klein-Schwartz; Jessica Youniss; S Rutherfoord Rose; Douglas Borys; Mary E May
Journal:  Am J Emerg Med       Date:  2003-09       Impact factor: 2.469

3.  The effect of activated charcoal on phenytoin pharmacokinetics.

Authors:  A M Rowden; J E Spoor; J S Bertino
Journal:  Ann Emerg Med       Date:  1990-10       Impact factor: 5.721

4.  Cerebellar atrophy following acute intoxication with phenytoin.

Authors:  H Masur; G Fahrendorf; C Oberwittler; G Reuther
Journal:  Neurology       Date:  1990-11       Impact factor: 9.910

5.  Inadvertent chronic diphenylhydantoin intoxication in a teenage girl.

Authors:  K P Herberg
Journal:  J S C Med Assoc       Date:  1972-09

6.  [Atrioventricular junctional arrhythmia due to oral phenytoin intoxication].

Authors:  R Magadle; P Weiner; J Waizman
Journal:  Harefuah       Date:  1999-03-15

7.  Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin.

Authors:  Jae-Gook Shin; Ji-Young Park; Min-Jung Kim; Ji-Hong Shon; Young-Ran Yoon; In-June Cha; Sang-Seop Lee; Se-Wook Oh; Sang-Woo Kim; David A Flockhart
Journal:  Drug Metab Dispos       Date:  2002-10       Impact factor: 3.922

8.  Treatment of phenytoin toxicity with repeated doses of activated charcoal.

Authors:  G D Weichbrodt; D P Elliott
Journal:  Ann Emerg Med       Date:  1987-12       Impact factor: 5.721

9.  Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin.

Authors:  T J O'Brien; G D Cascino; E L So; D R Hanna
Journal:  Neurology       Date:  1998-10       Impact factor: 9.910

10.  Pharmacokinetic simulation of the effect of multiple-dose activated charcoal in phenytoin poisoning--report of two pediatric cases.

Authors:  J G Dolgin; D E Nix; J Sanchez; W A Watson
Journal:  DICP       Date:  1991-06
View more
  25 in total

Review 1.  Drug-induced cerebellar ataxia: a systematic review.

Authors:  J van Gaalen; F G Kerstens; R P P W M Maas; L Härmark; B P C van de Warrenburg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

2.  Acute phenytoin intoxication in a 4-year-old mimicking viral meningoencephalitis.

Authors:  Amlin Shukla; Jhuma Sankar; Ankit Verma; Nandkishore Dubey
Journal:  BMJ Case Rep       Date:  2013-06-25

3.  Phenytoin-induced hypothermia.

Authors:  Marianne Watters; Hilary Wilson; Pamela Everitt
Journal:  BMJ Case Rep       Date:  2019-01-22

4.  Cardiac Collapse Secondary to Phenytoin Toxicity in a Neonate Treated with Extracorporeal Membrane Oxygenation Support (ECMO).

Authors:  Michelle Knecht; Joseph LaRochelle; Brian Barkemeyer; Raegan Gupta; Michael Brumund; Christy Mumphrey
Journal:  J Med Toxicol       Date:  2019-11-26

5.  A Rare Case of Junctional Bradycardia Secondary to Oral Phenytoin.

Authors:  Bilal A Niazi; Chinmay Trivedi; Benjamin Perrella
Journal:  Cureus       Date:  2022-05-23

6.  Levetiracetam as an alternative to phenytoin for second-line emergency treatment of children with convulsive status epilepticus: the EcLiPSE RCT.

Authors:  Richard E Appleton; Naomi Ea Rainford; Carrol Gamble; Shrouk Messahel; Amy Humphreys; Helen Hickey; Kerry Woolfall; Louise Roper; Joanne Noblet; Elizabeth Lee; Sarah Potter; Paul Tate; Nadia Al Najjar; Anand Iyer; Vicki Evans; Mark D Lyttle
Journal:  Health Technol Assess       Date:  2020-11       Impact factor: 4.014

7.  Recurrent takotsubo cardiomyopathy triggered by convulsive status epilepticus.

Authors:  Stephane Legriel; Fabrice Bruneel; Ludovic Dalle; Corinne Appere-de-Vecchi; Jean Louis Georges; Nathalie Abbosh; Matthieu Henry-Lagarrigue; Laure Revault D'Allonnes; Hager Ben Mokhtar; Juliette Audibert; Pierre Guezennec; Gilles Troche; Jean Pierre Bedos
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

Review 8.  Cardiovascular adverse effects of phenytoin.

Authors:  B Guldiken; J Rémi; Soheyl Noachtar
Journal:  J Neurol       Date:  2015-12-08       Impact factor: 4.849

9.  Phenytoin induced chorea in a pediatric patient: An interaction between phenytoin, phenobarbital and clobazam.

Authors:  Manish Barvaliya; Jayesh Sanmukhani; Tejas K Patel; C B Tripathi
Journal:  Indian J Pharmacol       Date:  2011-11       Impact factor: 1.200

Review 10.  Super-Refractory Status Epilepticus: Prognosis and Recent Advances in Management.

Authors:  Batool F Kirmani; Katherine Au; Lena Ayari; Marita John; Padmashri Shetty; Robert J Delorenzo
Journal:  Aging Dis       Date:  2021-07-01       Impact factor: 6.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.